Acumen Pharmaceuticals

ABOS46

Penny Stock

$2.67arrow_drop_down16.77%-$0.54

Penny Stock

ABOS46

$2.67

arrow_drop_down16.77%-$0.54

Penny Stock

Performance History

Key Stats
Open	$3.20
Prev. Close	$3.22
EPS	-1.11
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$193.45M
PE Ratio	-

	LOW	HIGH
Day Range	2.85	3.11
52 Week Range	1.81	5.09

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.11

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals, Inc. (ABOS) is a biopharmaceutical company that focuses on the development of innovative treatments for neurodegenerative diseases. The company's primary goal is to improve patients' quality of life by delivering groundbreaking therapies that target the underlying causes of these debilitating conditions. With a strong pipeline of potential drug candidates and a dedicated team of experts, Acumen Pharmaceuticals is well-positioned to make a significant impact in the field of neuroscience.

ABOS stock has shown promising performance in recent years, reflecting the market's confidence in the company's potential. The stock price history of Acumen Pharmaceuticals reveals a steady upward trend, with occasional fluctuations due to market dynamics. Investors seem to have recognized the value of the company's research and development efforts, leading to a positive trajectory for the stock.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Daniel J. O'Connell M.B.A.
Headquarters: Charlottesville
Employees: 39
Exchange: NASDAQ

Keep an eye on Acumen Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Acumen Pharmaceuticals's (ABOS) price per share?

The current price per share for Acumen Pharmaceuticals (ABOS) is $2.67. The stock has seen a price change of -$0.54 recently, indicating a -16.77% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Acumen Pharmaceuticals (ABOS)?

For Acumen Pharmaceuticals (ABOS), the 52-week high is $5.09, which is 90.28% from the current price. The 52-week low is $1.81, the current price is 47.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Acumen Pharmaceuticals (ABOS) a growth stock?

Acumen Pharmaceuticals (ABOS) has shown an average price growth of -3.67% over the past three years. It has received a score of 20 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Acumen Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Acumen Pharmaceuticals (ABOS) stock price performance year to date (YTD)?

As of the latest data, Acumen Pharmaceuticals (ABOS) has a year-to-date price change of -36.76%. Over the past month, the stock has experienced a price change of 13.83%. Over the last three months, the change has been 4.49%. Over the past six months, the figure is -20.39%.

help

Is Acumen Pharmaceuticals (ABOS) a profitable company?

Acumen Pharmaceuticals (ABOS) has a net income of -$52.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$61.14M. Furthermore, the EBITDA is -$76.62M.

help

What is the market capitalization of Acumen Pharmaceuticals (ABOS)?

Acumen Pharmaceuticals (ABOS) has a market capitalization of $160.71M. The average daily trading volume is 2.79, indicating the stock's liquidity and investor engagement.

News

ACUMEN PHARMACEUTICALS

ALZHEIMER'S DISEASE

AMYLOID BETA OLIGOMERS

CLINICAL TRIAL

Nov 6, 2024

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

ACUMEN PHARMACEUTICALS

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ACUMEN PHARMACEUTICALS

SABIRNETUG

ALZHEIMER'S DISEASE

AMYLOID BETA OLIGOMERS

BIOMARKERS

PATIENT EXPERIENCE

Jul 28, 2024

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

SMALL-CAP STOCKS

HIGH-RISK HIGH-REWARD

BIOTECH

ELECTRIC VEHICLES

Jul 24, 2024

4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com

CALENDAR OF EVENTS

May 13, 2024

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

CALENDAR OF EVENTS

May 8, 2024

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference